This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (56)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 2003;121:271-273.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Several authors have recently reported successful treatment of diabetic macular edema resistant to conventional laser photocoagulation with the injection of long-acting intravitreal corticosteroids.^1-2 Endophthalmitis after intravitreal injection is unusual. We report a case of Mycobacterium chelonae abscessus endophthalmitis occurring 1 month after the injection of intravitreal triamcinolone acetonide (Kenalog 40; Bristol-Myers Squibb Co, Princeton, NJ) to treat persistent diabetic macular edema.

Report of a Case

A 62-year-old man with a history of non–insulin dependent diabetes mellitus developed clinically significant macular edema. He underwent multiple sessions of focal grid argon laser photocoagulation to the edematous areas of the macula. Despite these sessions of focal grid macular laser photocoagulation, clinical examination showed persistent, widespread macular edema, and fluorescein angiography confirmed continued, diffuse macular leakage. With a visual acuity of 20/60 and no response to laser therapy, he underwent intravitreal injection of 4 mg of triamcinolone acetonide in 0.1 mL, 4 mm posterior to the limbus, using . . . [Full Text of this Article]

Comment
Corresponding author and reprints: Timothy G. Murray, MD, Bascom Palmer Eye Institute, PO Box 016880, Miami, FL 33101 (e-mail: tmurray@med.miami.edu).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema.
Kang et al.
Arch Ophthalmol 2006;124:653-658.
ABSTRACT | FULL TEXT  

Toxicity of Triamcinolone Acetonide on Retinal Neurosensory and Pigment Epithelial Cells
Narayanan et al.
IOVS 2006;47:722-728.
ABSTRACT | FULL TEXT  

Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jonas et al.
Arch Ophthalmol 2005;123:1338-1343.
ABSTRACT | FULL TEXT  

Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema
Spandau et al.
Br. J. Ophthalmol. 2005;89:999-1003.
ABSTRACT | FULL TEXT  

New Therapy for Central Retinal Vein Occlusion: Are Intravitreal Steroids a Possible Answer?
Blumenkranz
Arch Ophthalmol 2005;123:259-261.
FULL TEXT  

Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Jonas et al.
Br. J. Ophthalmol. 2004;88:1557-1562.
ABSTRACT | FULL TEXT  

Intravitreal Triamcinolone for the Management of Macular Edema Due to Nonischemic Central Retinal Vein Occlusion
Bashshur et al.
Arch Ophthalmol 2004;122:1137-1140.
ABSTRACT | FULL TEXT  

Authors' reply
Okada and Wakabayashi
Br. J. Ophthalmol. 2004;88:1102-1103.
FULL TEXT  

Morphallaxia-like ocular histology after intravitreal triamcinolone acetonide
Jonas and Bleyl
Br. J. Ophthalmol. 2004;88:839-840.
FULL TEXT  

Periocular corticosteroid therapy: comments
Vedantham
Br. J. Ophthalmol. 2004;88:724-725.
FULL TEXT  

Endophthalmitis After Intravitreal Injection of Triamcinolone Acetonide
Jonas et al.
Arch Ophthalmol 2003;121:1663-1664.
FULL TEXT